|Bid||1.1600 x 0|
|Ask||1.1700 x 0|
|Day's Range||1.1500 - 1.1750|
|52 Week Range||0.8700 - 1.6620|
|Beta (3Y Monthly)||0.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.44|
While Starpharma Holdings Limited (ASX:SPL) shareholders are probably generally happy, the stock hasn't had...
Starpharma has signed a Development and Option Agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product (DEP®) version of one of AstraZeneca’s major marketed oncology medicines. Following completion of agreed preclinical studies by Starpharma, AstraZeneca has the option to licence the DEP® oncology drug candidate for an option exercise fee of US$5M, plus industry standard development and commercialisation milestones and escalating royalties on sales.
In 2006 Jackie Fairley was appointed CEO of Starpharma Holdings Limited (ASX:SPL). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll consider...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices Read More...
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that the VivaGel® condom has received final regulatory approval and is now able to be marketed in Japan, following the completion of the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) review of the product's medical device classification and associated data. This final approval follows on from the previously granted regulatory certification, which was attained for the VivaGel® condom. Starpharma has worked closely with its commercial partner for Japan, Okamoto Industries (Okamoto), throughout the regulatory process.
A look at the shareholders of Starpharma Holdings Limited (ASX:SPL) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual Read More...